Pelvic Bone Metastases from Prostate Cancer
Prostate cancer spreads to bone more readily than to any other site, and the pelvis and lower spine are usually the first places it appears. This reflects both proximity and a specific venous pathway connecting the prostate directly to the bones of the pelvis and spine. Unlike most cancers, which dissolve bone as they grow, prostate cancer characteristically stimulates new bone formation, producing dense sclerotic deposits with a distinctive appearance on imaging. The finding changes the disease from localised to metastatic and shifts treatment goals toward long-term control rather than cure—but this is a setting where control can last many years, and where treatment has changed more in the past decade than in the several before it.
What is it?
A metastasis is a deposit of cancer that has travelled from its original site and established itself elsewhere. Prostate cancer has a marked tendency to spread to bone, and when it does, the pelvis and lower spine are typically involved first.
Two factors explain this pattern.
The first is anatomical. A network of valveless veins called Batson’s plexus connects the veins draining the prostate directly to those of the pelvis and vertebral column. Because these veins lack valves, blood can flow in either direction, particularly when pressure in the abdomen rises during coughing or straining. This provides a direct route from the prostate to the bones of the pelvis and spine that bypasses the usual circulation through the lungs, and it explains why these bones are affected first and most often.
The second is biological. Bone marrow provides an environment that suits prostate cancer cells particularly well, rich in growth factors and signalling molecules that support their survival. Tumour cells interact with the cells that normally build and break down bone, hijacking the continuous remodelling process that maintains the skeleton.
This interaction produces the most distinctive feature of prostate bone metastases. Most cancers that spread to bone are osteolytic—they activate the cells that dissolve bone, producing holes and weakening the structure. Prostate cancer is characteristically osteoblastic, or sclerotic: it stimulates the cells that lay down new bone, producing dense deposits that appear brighter than normal bone on imaging.
This has practical consequences. The new bone formed is disorganised and structurally poor despite being dense, so affected bone is still weaker than normal and can still fracture. The bone-forming activity is what a conventional bone scan detects, and it is also why alkaline phosphatase, an enzyme released during bone formation, is often elevated. And because the deposits are dense rather than destructive, they can persist on imaging long after treatment has controlled the cancer, which means an unchanged appearance on a scan does not necessarily mean treatment is failing—a point that causes considerable confusion.
In practice most deposits show a mixture of bone formation and destruction, with the balance varying between men and between sites.
The distribution follows the axial skeleton—the pelvis, spine, ribs, and the upper parts of the femurs and humeri—reflecting where red marrow with its rich blood supply persists in adults. The peripheral skeleton is affected less often and usually later.
Symptoms are frequently absent when deposits are first found, particularly when they are identified on staging imaging performed because of a high PSA or high-grade disease rather than because of any complaint.
When symptoms develop, bone pain is the most common. Its character is worth knowing, because it differs from the mechanical pain of arthritis or a strained back. Metastatic bone pain tends to be deep and persistent, present at rest, and often worse at night—in contrast to degenerative pain, which typically improves with rest and worsens with activity. It develops gradually over weeks and does not follow an obvious injury. Pain in the pelvis, hips, lower back, or thighs in a man with prostate cancer warrants assessment rather than being attributed to age or arthritis.
Complications of bone involvement, collectively termed skeletal-related events, are what much of the treatment aims to prevent. Pathological fracture occurs through weakened bone, sometimes after minimal trauma, most consequentially in the hip or femur. The need for radiotherapy or surgery to bone is itself counted among these events. Hypercalcaemia—a raised blood calcium level—occurs less often in prostate cancer than in osteolytic cancers because bone is being formed rather than dissolved, but it can still occur and causes thirst, confusion, constipation, and nausea.
Spinal cord compression is the most serious complication and deserves particular emphasis. Deposits in the vertebrae can expand into the spinal canal and press on the spinal cord or the nerve roots below it. Early symptoms include back pain, often worse when lying flat or with coughing, followed by leg weakness, numbness or altered sensation, difficulty walking, and loss of bladder or bowel control. The critical point is that neurological recovery depends heavily on how much function has been lost before treatment begins. A man who is still walking when treatment starts is far more likely to keep walking than one who has already lost the ability. This makes cord compression a genuine emergency requiring assessment within hours, and it is the single most important thing for men with bone metastases and their families to recognise.
Diagnosis and monitoring rely on imaging, and this area has changed substantially.
PSMA PET-CT has become the preferred test where available. It targets a protein expressed on the surface of prostate cancer cells, detecting deposits directly rather than the bone’s reaction to them. It identifies disease earlier and more accurately than conventional imaging, including in bones that look normal on other tests, and studies have shown it changes management in a meaningful proportion of men. Its sensitivity has also created a category of men found to have limited metastatic disease that previous imaging would have missed, which is an area of active research.
Bone scintigraphy—the conventional bone scan using technetium—remains widely used and available. It detects increased bone-forming activity rather than tumour cells, which makes it sensitive but not specific: arthritis, healed fractures, Paget disease of bone, and degenerative change all produce uptake and can be mistaken for metastases. Findings are interpreted alongside other imaging. A recognised phenomenon called the flare response can occur shortly after starting effective treatment, in which the scan appears worse because healing bone is highly active, despite the cancer responding. Repeating the scan after an interval clarifies this.
CT demonstrates the sclerotic deposits well, assesses the structural integrity of bone and the risk of fracture, and is used for radiotherapy and surgical planning.
MRI is the most sensitive test for disease within the bone marrow and detects deposits before they alter bone structure. It is the required investigation when spinal cord compression is suspected, imaging the whole spine because deposits are frequently multiple and a second site can be missed if only the symptomatic level is scanned.
PSA is the main blood marker for monitoring, though it is not infallible—a minority of advanced cancers produce relatively little PSA, and progression can occur with a stable level. Alkaline phosphatase reflects bone formation and correlates with the extent of bone involvement. Calcium, kidney function, and vitamin D are monitored, particularly during bone-targeted treatment.
Biopsy of a bone deposit is occasionally performed when the diagnosis is uncertain, when a solitary lesion could represent something else, or when tissue is needed for molecular testing to guide treatment.
Important to Know
The diagnosis of bone metastases means the cancer is no longer confined and is generally not curable, but it is important to be accurate about what that implies. Metastatic prostate cancer is frequently controlled for many years, treatment options have expanded substantially, and men often continue working, travelling, and living normally for extended periods. Care is coordinated by a multidisciplinary team including urology, medical and radiation oncology, palliative care, and specialists in bone health.
The most significant change in recent years is that hormonal therapy alone is no longer the standard for newly diagnosed metastatic disease. Multiple large trials have shown that adding a second agent from the outset—an androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide, or darolutamide, or chemotherapy with docetaxel in selected men—substantially improves survival compared with androgen deprivation alone. Triplet combinations are used in some situations. Men beginning treatment for metastatic prostate cancer should expect a discussion about combination therapy rather than hormonal treatment by itself, and it is entirely reasonable to ask specifically about this.
Bone-targeted therapy addresses the bone rather than the cancer. Zoledronic acid and denosumab reduce fractures, spinal cord compression, and the need for radiotherapy or surgery to bone. They are generally used once disease becomes resistant to hormonal treatment rather than from the outset, and are given with calcium and vitamin D supplementation. Both carry a risk of osteonecrosis of the jaw, which is uncommon but is the reason a dental assessment and any necessary dental work are arranged before starting treatment. Maintaining good dental care and informing any dentist about these medications is important throughout.
Radiotherapy is highly effective for painful bone deposits. A single treatment provides meaningful pain relief for a substantial majority of men, often within one to two weeks, and can be repeated. It is one of the most reliably effective interventions available for bone pain.
Radium-223 is a targeted radioactive treatment that concentrates in areas of active bone formation, delivering radiation directly to the deposits. It improves survival in men with symptomatic bone metastases without visceral spread. PSMA-targeted radioligand therapy delivers radiation to cells expressing PSMA and is used in appropriately selected men with advanced disease after other treatments.
Surgery is used to stabilise fractures and to prevent them where bone is severely weakened, and to decompress the spinal cord in selected cases of compression.
Spinal cord compression management is urgent. Corticosteroids are given immediately to reduce swelling, followed by radiotherapy or surgery depending on the situation, the stability of the spine, and the man’s overall condition. The essential message for men and families is that new back pain with any leg weakness, numbness, difficulty walking, or change in bladder or bowel control needs immediate assessment—not a routine appointment. Function preserved at the start of treatment is largely what will be retained afterwards.
Bone health during hormonal therapy deserves attention separate from the metastases themselves. Androgen deprivation therapy causes bone density loss and increases fracture risk independently of cancer, and this is often overlooked. Baseline bone density assessment, calcium and vitamin D, weight-bearing and resistance exercise, and bone-protective medication where indicated all form part of care.
Pain management extends beyond radiotherapy and includes analgesics used in a structured way, nerve-targeted treatments for specific pain patterns, and input from palliative care specialists, whose involvement improves quality of life and is appropriately introduced alongside active treatment rather than only at the end of it.
Side effects of long-term androgen deprivation are substantial and merit active management rather than acceptance: hot flushes, fatigue, muscle loss, weight gain, metabolic and cardiovascular changes, mood effects, and loss of libido and erectile function. Exercise has good evidence for mitigating several of these and is worth pursuing deliberately.
Genetic testing is recommended in metastatic prostate cancer. Identifying BRCA2 or other DNA repair mutations affects treatment options, including eligibility for PARP inhibitors, and has implications for relatives who may benefit from their own assessment.
An important interpretive point concerns follow-up scans. Because sclerotic deposits represent bone the body has built in response to tumour, they often remain visible—and can appear denser—even when treatment is working. Imaging is therefore interpreted alongside PSA, symptoms, and the overall clinical picture rather than in isolation, and a stable-looking scan is not evidence of failure.
Care is coordinated by a multidisciplinary team, and treatment at centres experienced in advanced prostate cancer provides access to the full range of options and to clinical trials, which are worth asking about given how rapidly this field is changing. Imaging, PSA, and clinical findings are interpreted together alongside the man’s overall health and priorities.
Patient education plays an important role. Understanding that metastatic prostate cancer is often controlled for years, that combination therapy from the outset is now standard, why dental assessment precedes bone-targeted treatment, that a single radiotherapy treatment often relieves bone pain, that scan appearances lag behind treatment response, and above all which symptoms signal cord compression all contribute to appropriate care.
Red flag symptoms include new or worsening back pain, particularly if it is worse lying flat or when coughing; any new leg weakness, numbness, tingling, heaviness, or difficulty walking; loss of bladder or bowel control, or new difficulty passing urine; a band-like sensation around the chest or abdomen; sudden severe pain in a bone, particularly after minor or no injury, suggesting fracture; inability to bear weight; and confusion, excessive thirst, nausea, or constipation, which may indicate a raised calcium level. New leg weakness, sensory change, or bladder or bowel dysfunction requires immediate emergency assessment, as spinal cord compression is time-critical and function lost before treatment is often not recovered.